EGFR mutant-selective inhibitor FWD1509 MsOH

{
  "id": "MLC-T-ONC-013257",
  "term": "EGFR mutant-selective inhibitor FWD1509 MsOH",
  "field": "Oncology and biomedicine",
  "definition": "The methanesulfonic acid salt form of FWD1509, an orally bioavailable, irreversible, small molecule, mutant-selective inhibitor of epidermal growth factor receptor (EGFR), with potential antineoplastic activity. Upon oral administration, EGFR mutant-selective inhibitor FWD1509 MsOH targets, binds to, and inhibits the activity of EGFR with exon20 insertion mutations, as well as L858R, exon19del and T790M mutations, thereby preventing EGFR-mediated signaling. This may both induce cell death and inhibit tumor growth in EGFR-overexpressing tumor cells. EGFR, a receptor tyrosine kinase mutated in many tumor cell types, plays a key role in tumor cell proliferation and tumor vascularization. FWD1509 MsOH is able to cross the blood-brain barrier (BBB).",
  "synonyms": [
    "FWD1509 methanesulfonic acid"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/egfr-mutant-selective-inhibitor-fwd1509-msoh/"
}